What is HC Wainwright's Forecast for TARS FY2027 Earnings?

Key Points

• HC Wainwright raised its FY2027 earnings per share (EPS) forecast for Tarsus Pharmaceuticals to $0.80, up from a previous estimate of $0.76, while maintaining a "Buy" rating and a price target of $72.00.
• Recent earnings data revealed that Tarsus Pharmaceuticals reported an EPS of ($0.48) for the latest quarter, missing analyst expectations, despite achieving revenue of $102.66 million.
• Over 90% of Tarsus Pharmaceuticals' stock is held by institutional investors, indicating strong investment confidence in the company.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Research analysts at HC Wainwright boosted their FY2027 earnings estimates for Tarsus Pharmaceuticals in a research note issued to investors on Thursday, August 7th. HC Wainwright analyst M. Caufield now forecasts that the company will earn $0.80 per share for the year, up from their previous forecast of $0.76. HC Wainwright currently has a "Buy" rating and a $72.00 target price on the stock. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals' FY2029 earnings at $1.07 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.15). The company had revenue of $102.66 million during the quarter, compared to analyst estimates of $95.81 million. Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%.

A number of other brokerages have also commented on TARS. The Goldman Sachs Group boosted their price objective on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Guggenheim boosted their price objective on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They set an "outperform" rating and a $75.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $66.67.

Tarsus Pharmaceuticals Stock Up 2.6%

Shares of TARS stock traded up $1.29 during trading on Friday, reaching $51.36. The company's stock had a trading volume of 609,887 shares, compared to its average volume of 661,776. The business has a fifty day moving average price of $41.67 and a 200-day moving average price of $45.67. The company has a quick ratio of 5.21, a current ratio of 5.26 and a debt-to-equity ratio of 0.22. The company has a market cap of $2.17 billion, a price-to-earnings ratio of -22.04 and a beta of 0.79. Tarsus Pharmaceuticals has a one year low of $24.95 and a one year high of $57.28.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TARS. Pictet Asset Management Holding SA bought a new position in shares of Tarsus Pharmaceuticals during the fourth quarter worth approximately $284,000. Geode Capital Management LLC increased its position in Tarsus Pharmaceuticals by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 838,804 shares of the company's stock worth $46,456,000 after acquiring an additional 3,014 shares during the period. Wells Fargo & Company MN increased its position in Tarsus Pharmaceuticals by 44.1% during the fourth quarter. Wells Fargo & Company MN now owns 57,004 shares of the company's stock worth $3,156,000 after acquiring an additional 17,451 shares during the period. Federated Hermes Inc. bought a new position in Tarsus Pharmaceuticals during the fourth quarter worth about $4,303,000. Finally, Invesco Ltd. increased its position in Tarsus Pharmaceuticals by 36.7% during the fourth quarter. Invesco Ltd. now owns 932,115 shares of the company's stock worth $51,611,000 after acquiring an additional 250,018 shares during the period. 90.01% of the stock is owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.